Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy
New England Journal of Medicine · 30.07.2026 · 395 (5) · 440-453
DOI: 10.1056/nejmoa2603870 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 30.07.2026. Verfasst von Cyrille Touzeau und 48 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, University Hospital of Nantes, Nantes, France. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology, University Hospital of Nantes, Nantes, France.
- Division of Hematology, Department of Molecular Biotechnology and Health Sciences, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy.
- Winship Cancer Institute, Emory University, Atlanta.
- University of Melbourne, St. Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
- Clinica São Germano, São Paulo.
- Columbia University Medical Center, New York.
ORCID-Profile: Chakra Chaulagain, Khalid Saja, Cirino Botta, Aurore Perrot, Ola Landgren
Förderung
- Johnson & Johnson
Zitieren
APA
Touzeau, C., Mina, R., Quach, H., Hungria, V., Bhutani, D., Chen, W., Kumar, S., Chaulagain, C., Dimopoulos, M. A., Bahlis, N. J., Maral, S., van de Donk, N. W. C. J., Schmidt Filho, J., Saja, K., Teipel, R., Ando, M., Roeloffzen, W., Annibali, O., Augustson, B., …, & MajesTEC-9 Trial Investigators (2026). Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. New England Journal of Medicine, 395(5), 440-453. https://doi.org/10.1056/nejmoa2603870
Vancouver
Touzeau C, Mina R, Quach H, Hungria V, Bhutani D, Chen W, et al. Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy. New England Journal of Medicine. 2026;395(5):440-453. doi:10.1056/nejmoa2603870
BibTeX
@article{Touzeau2026,
author = {Touzeau, Cyrille and Mina, Roberto and Quach, Hang and Hungria, Vania and Bhutani, Divaya and Chen, Wenming and Kumar, Swarup and Chaulagain, Chakra and Dimopoulos, Meletios Athanasios and Bahlis, Nizar J and Maral, Senem and van de Donk, Niels W C J and Schmidt Filho, Jayr and Saja, Khalid and Teipel, Raphael and Ando, Miki and Roeloffzen, Wilfried and Annibali, Ombretta and Augustson, Bradley and Botta, Cirino and Delforge, Michel and Bourgeois, Emmanuelle and Buda, Gabriele and Hus, Marek and Perrot, Aurore and Preis, Meir and Beksac, Meral and Pour, Ludek and Farmer, Sarah and Nunes, Marta and Oriol, Albert and Melchardt, Thomas and Hu, Yu and Flogegård, Max and Wang, Dai and Pei, Lixia and Wroblewski, Susan and Ariës, Ingrid M and Quijano Cardé, Natalia A and Perova, Tatiana and de Jager, Tertia and Yeh, Tzu-Min and Vanquickelberghe, Veronique and Shah, Priya and Chastain, Katherine and Kobos, Rachel and Carson, Robin and Landgren, Ola and MajesTEC-9 Trial Investigators, MajesTEC-9 Trial Investigators},
title = {Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {5},
pages = {440--453},
doi = {10.1056/nejmoa2603870}
}
EUVIMED